XOLAIR 75 mg Solution for injection Ref.[7999] Active ingredients: Omalizumab

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Product name and form

Xolair 75 mg solution for injection in pre-filled syringe.

Xolair 75 mg solution for injection in pre-filled pen.

Pharmaceutical Form

Solution for injection (injection).

Clear to slightly opalescent, colourless to pale brownish-yellow solution.

Qualitative and quantitative composition

Xolair 75 mg solution for injection in pre-filled syringe: Each pre-filled syringe contains 75 mg of omalizumab* in 0.5 ml solution.

Xolair 75 mg solution for injection in pre-filled pen: Each pre-filled pen contains 75 mg of omalizumab* in 0.5 ml solution.

* Omalizumab is a humanised monoclonal antibody produced in a Chinese hamster ovary (CHO) mammalian cell line by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Omalizumab

Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and lowers free IgE levels. The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE.

List of Excipients

Arginine hydrochloride
Histidine hydrochloride monohydrate
Histidine
Polysorbate 20
Water for injections

Pack sizes and marketing

Xolair 75 mg solution for injection in pre-filled syringe (26-gauge staked needle, blue syringe guard)

Xolair 75 mg solution for injection in pre-filled syringe is supplied as 0.5 ml solution in a pre-filled syringe barrel (type I glass) with 26-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.

Pack sizes: packs containing 1 pre-filled syringe, and multipacks containing 4 (4 × 1) or 10 (10 × 1) pre-filled syringes.

Xolair 75 mg solution for injection in pre-filled syringe (27-gauge staked needle, blue plunger)

Xolair 75 mg solution for injection in pre-filled syringe is supplied as 0.5 ml solution in a pre-filled syringe barrel (type I glass) with 27-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.

Pack sizes: packs containing 1 pre-filled syringe, and multipacks containing 3 (3 × 1) or 6 (6 × 1) pre-filled syringes.

Xolair 75 mg solution for injection in pre-filled pen

Xolair 75 mg solution for injection in pre-filled pen is supplied as 0.5 ml solution in a pre-filled pen barrel (type I glass) with 27-gauge staked needle (stainless steel), (type I) plunger stopper and needle cap.

Pack sizes: packs containing 1 pre-filled pen, and multipacks containing 3 (3 × 1) or 6 (6 × 1) pre-filled pens.

Not all pack sizes may be marketed.

Marketing authorization holder

Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Marketing authorization dates and numbers

Xolair 75 mg solution for injection in pre-filled syringe:

EU/1/05/319/005
EU/1/05/319/006
EU/1/05/319/007
EU/1/05/319/018
EU/1/05/319/019
EU/1/05/319/020

Xolair 75 mg solution for injection in pre-filled pen:

EU/1/05/319/021
EU/1/05/319/022
EU/1/05/319/023

Date of first authorisation: 25 October 2005
Date of latest renewal: 22 June 2015

Drugs

Drug Countries
XOLAIR Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.